ABIO ARCA Bio: Rasio rega marang prakiraan pendapatan

Logo korporat perusahaan ARCA Biopharma, Inc. (ABIO)

ARCA Biopharma (ABIO) is developing a high-tech precision cardiology therapy environment, linking genetics with unique molecules. The forward P/S valuation reflects market expectations, with the indicator standing at . Current valuation is based on liquidity and confidence in future patents. High barriers to entry are ensured by costly clinical trials and strict intellectual property protection.

ARCA Biopharma, Inc. - Rega forward marang dodolan ABIO (periode 04.07.2022 - 16.11.2026)

Rincian metrik komprehensif lan analitis ARCA Biopharma Inc (ABIO)

- data kapitalisasi saham perusahaan:
Analisis kabeh metrik perusahaan:ARCA Biopharma ABIO
Produk asli ARCA Biopharma, Inc.

To identify the sector's fundamental leaders, the analyst evaluates the ratio of market capitalization to expected annual sales, which allows for the filtering of market noise. This calculation, which accounts for the stability of biomaterial supplies through the secured contracts of ARCA Biopharma (ABIO), reflects the dynamics of business revaluation, where any trend on the forward P/S chart signals either a recovery in value or an impending correction.